Xponance Inc. boosted its position in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 2.9% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 332,707 shares of the company’s stock after acquiring an additional 9,465 shares during the quarter. Johnson & Johnson accounts for approximately 0.8% of Xponance Inc.’s investment portfolio, making the stock its 21st biggest position. Xponance Inc.’s holdings in Johnson & Johnson were worth $51,570,000 at the end of the most recent quarter.
A number of other hedge funds also recently bought and sold shares of JNJ. Glassy Mountain Advisors Inc. acquired a new stake in Johnson & Johnson in the 4th quarter valued at about $35,000. GW&K Investment Management LLC acquired a new stake in shares of Johnson & Johnson during the 4th quarter worth about $35,000. Dark Forest Capital Management LP raised its position in shares of Johnson & Johnson by 1,044.4% during the 4th quarter. Dark Forest Capital Management LP now owns 206 shares of the company’s stock worth $36,000 after acquiring an additional 188 shares in the last quarter. Retirement Financial Solutions LLC acquired a new stake in shares of Johnson & Johnson during the 4th quarter worth about $40,000. Finally, Ruedi Wealth Management Inc. acquired a new stake in shares of Johnson & Johnson during the 4th quarter worth about $42,000. Institutional investors and hedge funds own 67.57% of the company’s stock.
Analyst Upgrades and Downgrades
Several brokerages have recently weighed in on JNJ. UBS Group began coverage on Johnson & Johnson in a research report on Tuesday, March 28th. They set a “neutral” rating and a $164.00 target price on the stock. Atlantic Securities cut their target price on Johnson & Johnson from $168.00 to $167.00 and set a “neutral” rating on the stock in a research report on Wednesday, April 19th. TheStreet downgraded Johnson & Johnson from a “b” rating to a “c+” rating in a research note on Friday, May 19th. Morgan Stanley raised their price target on Johnson & Johnson from $179.00 to $183.00 and gave the stock an “equal weight” rating in a research note on Wednesday, April 19th. Finally, StockNews.com assumed coverage on Johnson & Johnson in a research note on Thursday, May 18th. They set a “strong-buy” rating on the stock. Seven research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $171.57.
Insider Activity at Johnson & Johnson
Johnson & Johnson Trading Down 1.4 %
Shares of JNJ stock opened at $163.26 on Tuesday. The business’s 50 day moving average is $160.78 and its two-hundred day moving average is $162.82. Johnson & Johnson has a twelve month low of $150.11 and a twelve month high of $181.04. The company has a market capitalization of $424.27 billion, a P/E ratio of 34.15, a price-to-earnings-growth ratio of 2.83 and a beta of 0.55. The company has a current ratio of 1.07, a quick ratio of 0.85 and a debt-to-equity ratio of 0.49.
Johnson & Johnson (NYSE:JNJ – Free Report) last posted its quarterly earnings results on Tuesday, April 18th. The company reported $2.68 earnings per share for the quarter, beating analysts’ consensus estimates of $2.51 by $0.17. Johnson & Johnson had a return on equity of 36.13% and a net margin of 13.22%. The firm had revenue of $24.75 billion for the quarter, compared to the consensus estimate of $23.61 billion. During the same period in the previous year, the business earned $2.67 earnings per share. The company’s revenue for the quarter was up 5.6% compared to the same quarter last year. Equities analysts forecast that Johnson & Johnson will post 10.66 EPS for the current year.
Johnson & Johnson Increases Dividend
The firm also recently declared a quarterly dividend, which was paid on Tuesday, June 6th. Investors of record on Tuesday, May 23rd were paid a $1.19 dividend. The ex-dividend date of this dividend was Monday, May 22nd. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.13. This represents a $4.76 dividend on an annualized basis and a dividend yield of 2.92%. Johnson & Johnson’s payout ratio is 99.58%.
Johnson & Johnson Profile
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.
Featured Stories
- Five stocks we like better than Johnson & Johnson
- Tesla Production Cranks Into High Gear, Shares Follow
- Ford Soars 30% YTD After Breaking Out: What’s Next?
- Acuity Brands Lights Up Opportunity In The Industrial Sector
- Overstock Looks Beyond Overbought After Bed Bath Re-Brand
- Tecnoglass Shines Bright As Analysts Bullish On Growth Potential
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
